34
Views
11
CrossRef citations to date
0
Altmetric
Miscellaneous

TRICOM: enhanced vaccines as anticancer therapy

, &
Pages 397-402 | Published online: 09 Jan 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Ravi A Madan, Philip M Arlen & James L Gulley. (2007) PANVAC™-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma. Expert Opinion on Biological Therapy 7:4, pages 543-554.
Read now
Robert C. Ward & Howard L. Kaufman. (2007) Targeting Costimulatory Pathways for Tumor Immunotherapy. International Reviews of Immunology 26:3-4, pages 161-196.
Read now

Articles from other publishers (9)

Wenqing Jia, Tao Zhang, Haiyan Huang, Haoran Feng, Shaodong Wang, Zichao Guo, Zhiping Luo, Xiaopin Ji, Xi Cheng & Ren Zhao. (2022) Colorectal cancer vaccines: The current scenario and future prospects. Frontiers in Immunology 13.
Crossref
Olivier Manches, Luciana R. Muniz & Nina Bhardwaj. 2018. Hematology. Hematology 247 260.e6 .
Manzoor M KhanManzoor M. Khan. 2016. Immunopharmacology. Immunopharmacology 363 396 .
Parminder Singh, Sumanta K Pal, Anitha Alex & Neeraj Agarwal. (2015) Development of PROSTVAC immunotherapy in prostate cancer. Future Oncology 11:15, pages 2137-2148.
Crossref
Margaret K. Callahan, Jedd D. Wolchok, James P. Allison & Padmanee Sharma. 2013. Cancer Immunotherapy. Cancer Immunotherapy 211 280 .
Manzoor M. KhanManzoor M. Khan. 2008. Immunopharmacology. Immunopharmacology 227 252 .
Douglas W. Grosenbach, Jarett Feldman, Jeffrey Schlom & Scott I. Abrams. 2007. General Principles of Tumor Immunotherapy. General Principles of Tumor Immunotherapy 217 250 .
RS DiPaola, M Plante, H Kaufman, DP Petrylak, R Israeli, E Lattime, K Manson & T Schuetz. (2006) A Phase I Trial of Pox PSA vaccines (PROSTVAC®-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM™) in Patients with Prostate Cancer. Journal of Translational Medicine 4:1.
Crossref
Dan Laheru & Elizabeth M. Jaffee. (2005) Immunotherapy for pancreatic cancer — science driving clinical progress. Nature Reviews Cancer 5:6, pages 459-467.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.